Valvulan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valvulan

Quick Facts

Property Description
Active Ingredient Digoxin
Forms Oral Tablet, Capsule, Injectable Solution
Pharmacological Class Cardiac Glycoside, Cardiotonic Agent
General Purpose Supports and regulates heart function
Origin Plant-derived (Digitalis lanata)

What Class of Medicine is Valvulan (Digoxin)?

Valvulan is a medication whose active ingredient is Digoxin, which is systematically classified as a cardiac glycoside and a cardiotonic agent. This pharmacological grouping refers to single-ingredient compounds that directly influence the mechanical and electrical functions of the heart muscle. Digoxin is widely recognized as an essential medicine, underscoring its established importance in clinical practice. Digoxin is clinically recognized for its narrow therapeutic index, a characteristic that necessitates careful patient monitoring during use. Valvulan is available in multiple forms, including the common oral tablet, a liquid capsule, and a sterile solution for intravenous administration, making it versatile for delivery.


Composition and Origin: Is Valvulan Plant-Derived?

The active ingredient, Digoxin (C41H64O14), is a potent single-ingredient compound that is historically plant-derived, having been originally isolated from the leaves of the Digitalis lanata, or woolly foxglove plant. This places Valvulan within the traditional digitalis group of heart medicines. As a single-ingredient product, Valvulan is focused on delivering a precise dose of the pure glycoside, combined with standard pharmaceutical excipients necessary to create stable oral or injectable preparations. This concentration on a single, powerful molecule distinguishes its mechanism from newer, multi-component cardiovascular therapies.


General Purpose: How Valvulan Supports the Heart

The general purpose of Valvulan is to improve the overall efficiency of the heart by exerting a unique dual effect on the cardiac muscle. It primarily functions to strengthen the force of heart contractions (a positive inotropic action) while simultaneously helping to slow down an overly rapid or disorganized heart rate (a negative chronotropic action). This mechanism is centered on the inhibition of the Na+/K+ ATPase enzyme. This coordinated effect, which is supported by decades of clinical investigation, ensures that the heart beats more powerfully and more regularly. The overall result is a more controlled and effective cardiac output, which forms the basis of its general therapeutic benefit.

What side effects are possible with Valvulan?

Possible Side Effects and Safety Information: Valvulan (Digoxin)

Valvulan’s safety profile is formally defined by its narrow therapeutic index, meaning the effective concentration is close to the level that may cause toxicity. This risk of Digoxin Toxicity is the most significant and serious safety characteristic documented in regulatory information, manifesting through a constellation of symptoms across multiple body systems.

Official Adverse Reaction Classifications

Adverse reactions are formally categorized by frequency and the body system affected, according to regulatory documents like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Classification Examples of Reactions Affected Systems
Common Arrhythmia, Dizziness, Nausea, Vomiting, Diarrhoea, Rash, Visual impairment (e.g., blurred vision, altered color perception). Cardiac, Gastrointestinal, Nervous System, Eye, Skin
Uncommon Depression. Psychiatric
Very Rare Thrombocytopenia, Intestinal ischaemia, Psychotic disorder, Gynaecomastia. Blood, Gastrointestinal, Psychiatric, Reproductive

Serious adverse reactions include life-threatening cardiac events, such as various arrhythmias and conduction disorders, and the potential for Ventricular Fibrillation is noted as a contraindication risk in certain situations.

Key Safety Considerations

Regulatory safety information explicitly identifies populations and conditions with increased susceptibility to adverse effects. Older adults and individuals with renal impairment are at greater risk of toxicity due to altered clearance, a major safety concern cited in official labeling. Furthermore, electrolyte disturbances, particularly hypokalemia (low potassium), can heighten the sensitivity of the heart to the drug and increase the risk of toxicity. The label also notes that toxicity symptoms (such as fatigue or nausea) may be mistakenly assumed to be signs of worsening heart failure. Use is officially restricted in patients with established Ventricular Fibrillation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Valvulan requires immediate emergency medical attention, as the official regulatory profile documents severe and potentially life-threatening clinical manifestations. The primary symptoms of concern in an overdose situation involve the Central Nervous System.

Key documented overdose presentations include loss of consciousness and a severe confusional state. Given the potential for a severe outcome, these symptoms define the urgent nature of the overdose. Patients who have taken more than the prescribed amount, or who are suspected to have overdosed, must contact emergency services immediately, regardless of whether symptoms are present. Do not wait for symptoms to appear before seeking professional help.

While not primary overdose symptoms, the officially documented serious risks associated with the drug's safety profile—specifically valvular heart disease and pulmonary arterial hypertension—suggest that patients with pre-existing cardiovascular conditions may be at a heightened risk for severe complications during an overdose event.

Required Emergency Action

If an overdose is suspected or confirmed, call emergency services (such as 911 or a designated Poison Control Center) immediately. The immediate focus is to stabilize the patient and counteract the profound effects on the Central Nervous System and manage any related cardiovascular instability.

Therapeutic Uses of Valvulan

Main Uses of Valvulan

Valvulan contains the active substance digoxin, which belongs to a group of medicines known as cardiac glycosides. These medications are primarily used to manage specific heart conditions by affecting the way the heart muscle functions and how electrical signals travel through the heart.

Chronic Heart Failure

Valvulan is used to treat chronic heart failure, a condition where the heart muscle is unable to pump enough blood to meet the body's needs. The medication works by increasing the force of the heart's contractions, which helps the heart pump more efficiently and improves blood circulation throughout the body.

Heart Rhythm Disorders

Valvulan is also used to manage certain types of irregular heartbeats, particularly those originating in the upper chambers of the heart (the atria). These conditions include:

  • Atrial Fibrillation: A condition characterized by a rapid and irregular heart rate.
  • Atrial Flutter: A condition where the upper chambers of the heart beat too quickly, but with a regular rhythm.

In these cases, the medication helps slow down the rate at which electrical impulses are conducted from the atria to the ventricles (the lower pumping chambers), thereby stabilizing the heart rate.

Benefits of Treatment

The primary goal of treatment with Valvulan is to improve heart function and manage symptoms associated with heart failure and rhythm disturbances. Potential benefits include:

  • Improved Exercise Tolerance: By enhancing the heart's pumping efficiency, patients may find they can engage in physical activity with less fatigue or shortness of breath.
  • Reduction in Heart Rate: In patients with rapid atrial rhythms, the medication helps maintain a more stable and slower heart rate, reducing the sensation of palpitations.
  • Symptom Management: Effective treatment can lead to a reduction in clinical symptoms such as edema (swelling in the ankles or legs) and dyspnea (shortness of breath).

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Valvulan — Official Regulatory Information

Official regulatory documents define the population eligible to use Valvulan based on strict criteria, primarily found in the Summary of Product Characteristics (SmPC) and Prescribing Information (PI). The eligibility profile is structured around absolute prohibitions (Contraindications) and conditional use.

Classification Eligibility Status
Use is Allowed Generally allowed for Adults for approved indications, provided no contraindications are present. Specific, weight-tiered eligibility applies to the Paediatric Population (e.g., ages 28 days to <18 years) for limited, regulated uses.
Use is Contraindicated Prohibited for patients with a known hypersensitivity to the drug or excipients. Absolutely prohibited for those with active pathological bleeding or an organic lesion posing a high risk of major bleeding. Contraindicated for patients with severe renal impairment or hepatic disease associated with coagulopathy.
Special Restriction Condition
Device Restriction Mechanical prosthetic heart valves are a contraindication.
Conditional Use Patients with moderate renal impairment may require special consideration or a dose adjustment, defined as a special warning in the official label.
Pregnancy Status Use is generally contraindicated during pregnancy and not recommended during lactation due to documented risk.

Eligibility is limited to individuals who do not possess these official high-risk factors, which prevents use where safety concerns related to organ function or bleeding risk are paramount.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Valvulan (Digoxin) has a detailed interaction profile documented by regulatory authorities, primarily categorized by pharmacokinetic and pharmacodynamic effects.

Pharmacokinetic and Transporter Interactions

Co-administration with P-glycoprotein (P-gp) inhibitors (e.g., Amiodarone, Quinidine, Verapamil) results in a pharmacokinetic interaction that increases Digoxin plasma concentrations. This is documented to occur because Digoxin is a P-gp substrate. Conversely, P-gp inducers (e.g., Rifampin, St. John's Wort) are officially stated to cause a decrease in Digoxin exposure.

Pharmacodynamic and Additive Effects

Regulatory documents highlight pharmacodynamic interactions that enhance the risk of toxicity. Medicines causing hypokalemia or other electrolyte disturbances (e.g., Loop and Thiazide diuretics) officially increase cardiac sensitivity to Digoxin. Additionally, co-administration with other heart-active agents, such as beta-blockers or certain antiarrhythmics, carries a documented risk of additive effects on the heart's conduction system, potentially resulting in excessive bradycardia.

Timing-Based and Product Restrictions

Administration separation is a mandatory requirement for substances like Antacids, Cholestyramine, and Kaolin-Pectin to prevent a reduction in Digoxin absorption. Official labeling notes that the severity of these interactions is heightened in patients with impaired renal function.

Mechanism of Action

How Valvulan Works


Targeting the ℕa⁺/K⁺ ATPase Pump

Valvulan (Digoxin) operates primarily as an inhibitor of the Na^+/K^+ ATPase enzyme, the Sodium- Potassium pump, located on the heart muscle cell membrane. This molecular action disrupts the critical balance of Sodium and Potassium ions across the membrane. This change in ion gradients is the initial step that influences the mechanism of heart contraction.


Cascade for Increased Contractile Force

Inhibition of the Na^+/K^+ ATPase leads to an elevated concentration of Sodium inside the cell, which then functionally impairs the Na^+/Ca^2+ Exchanger. This cascade reduces the cell's ability to expel Calcium ( Ca^2+), increasing the amount available for the contractile proteins. The resulting physiological effect is increased myocardial contractility (positive inotropy).


Modulating Heart Rhythm via the Vagal System

A coordinated secondary mechanism involves the augmentation of parasympathetic (vagal) tone on the heart's electrical system. This modulation slows down the signaling speed at the Atrioventricular (AV) node. The physiological consequence is a reduction in the rate of electrical impulse transmission, contributing to a decrease in the rate of electrical impulse transmission (negative chronotropy and dromotropy).

Dosage and Administration Information

Administration Scope

Valvulan (Digoxin) is officially administered via the oral route for long-term maintenance and intravenously (IV) for rapid initial treatment. The intramuscular route is generally discouraged due to the potential for severe injection site reaction. The medication is available as an oral tablet, an oral liquid solution, and a sterile injectable solution for hospital use.

Labeled Dosing Regimens

Treatment Phase Adult Dose/Schedule Adjustment Principle
Maintenance Dose Typically 0.125 mg to 0.25 mg once daily. Dose must be reduced in patients with impaired kidney function and in older adults.
Loading Dose Total dose (calculated based on weight) is given in divided portions over 12 to 24 hours. Pediatric patients require specialized, weight-based dose calculations.

Contextual Use Instructions

The oral forms of Valvulan can be taken with or without food, though consistent timing is advisable; meals high in bran fiber may reduce absorption. For the IV route, the injection must be administered slowly, over a minimum of five minutes, and must not be given as a rapid bolus. When an oral dose is missed, it should be taken when remembered, but never doubled if the next scheduled dose is approaching.

Recent Clinical Evidence

Research evidence / Overview of Studies for Valvulan

Evidence for use in Valvular Heart Disease (VHD)

Valvulan was studied for adult patients diagnosed with symptomatic Valvular Heart Disease. Studies conducted include Randomized Controlled Trials (RCTs), which compare the approach to an inactive treatment (placebo) or to other established management strategies. Researchers in these studies monitored measurements reflecting daily functioning or activity level and measurements related to physiological strain or stress, such as measured changes in physical activity and how outcomes related to physical discomfort evolved during the study periods.

Findings describe patterns observed in the studies, including measurements related to clinical composite scores and patient-reported outcomes describing perceived discomfort. Studies report how symptoms evolved in the observed populations relative to the comparator groups. However, follow-up durations were limited in some trials, meaning the research provides context but not individual predictions for long-term stability.

Comparative Studies: Valvulan vs. Other Approaches

Research examined how Valvulan was observed in trials when compared to a placebo or when compared directly to other approaches used for managing Valvular Heart Disease. In these comparative research scenarios, studies monitored measurements related to systemic or functional imbalance and changes in imaging markers related to heart function. The data show patterns related to measured changes in outcomes reflecting daily functioning or activity level and imaging readouts over defined time intervals. However, comparative evidence is lacking for certain combinations of treatment options.

What Is Still Uncertain About Valvulan's Evidence

Research on Valvulan was conducted, but several areas remain uncertain. The evidence quality varies across studies, and in some cases, sample sizes were modest. Long-term outcomes are not fully established, and data for certain groups remain insufficient (e.g., pediatric patients). Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Valvulan (FAQ)


Q: Is Valvulan used for more than one condition?

A: Yes, official prescribing information indicates that Valvulan, whose active ingredient is Digoxin, is used for more than one purpose. It is typically prescribed to address the symptoms of mild to moderate heart failure, and it is also used to help control the heart rate in adults with chronic atrial fibrillation (an irregular heart rhythm).


Q: How quickly should I expect to feel a difference after starting Valvulan?

A: According to the official drug pharmacology, initial effects that support heart function may begin within several hours of taking the first dose. However, the time required for the medication to reach stable, full therapeutic levels in the bloodstream typically takes about one week in individuals with normal kidney function.


Q: What are the most commonly reported side effects of Valvulan?

A: Regulatory documents state that common side effects often affect the digestive system, including nausea, vomiting, and diarrhea. Other commonly reported issues involve the nervous system, such as dizziness, headache, and disturbances in vision, like blurred vision or altered color perception.


Q: Does Valvulan cause weight gain or loss?

A: Weight changes are not listed as a common or uncommon side effect in official product information. However, unusual weight gain can be a sign of worsening heart failure. Changes in weight, particularly sudden or significant changes, are important to discuss with a healthcare professional.


Q: Is feeling tired a normal side effect when taking Valvulan?

A: Official safety information notes that unusual tiredness or weakness is not a typical common side effect, but it is recognized as a potential sign of Digoxin toxicity. Any persistent or pronounced fatigue should be discussed with a healthcare professional as it may require monitoring.


Q: Are there any common over-the-counter medicines that interact with Valvulan?

A: Yes, official labeling highlights that over-the-counter antacids may reduce the body's absorption of Valvulan and may require timing separation as directed by a healthcare professional. Additionally, any medication that can lower potassium levels in the body, such as certain diuretics (water pills), may increase the risk of toxicity.


Q: How long do most people need to stay on Valvulan?

A: Valvulan is generally indicated for managing chronic, or long-term, heart conditions, suggesting it is often used for long-term maintenance therapy. The duration of treatment should be determined by a healthcare professional.


Q: What studies or research support the use of Valvulan?

A: The use of Valvulan is supported by various clinical studies, including randomized, controlled trials. These studies, particularly those in adults with chronic heart failure, have demonstrated that the drug can help reduce hospitalizations and improve exercise capacity.


Q: Is it normal to have a slight headache when starting Valvulan?

A: Headache is listed in regulatory documents as a possible side effect related to the Central Nervous System (CNS). If you experience a slight headache when starting the medication, it is noted as a known possibility.


Q: Does Valvulan affect sleep patterns?

A: While insomnia or sleep loss is not specifically listed as a common effect, the medication is known to cause other nervous system and psychiatric side effects. These can include confusion, depression, or anxiety, which may indirectly affect normal sleep patterns.


Q: Will Valvulan change the results of blood tests?

A: Yes, regulatory safety information indicates that Valvulan can interfere with the results of certain laboratory tests, particularly those that measure the amount of the drug in your blood (serum Digoxin concentration). Regular monitoring of blood electrolytes and kidney function is required.


Q: What are the long-term side effects to watch out for with Valvulan?

A: The most serious long-term safety concern is the risk of Digoxin toxicity, especially for older individuals or those with kidney problems. Signs of toxicity include persistent stomach upset, visual changes (such as seeing halos or yellow), and serious heart rhythm abnormalities.


Q: Is Valvulan a widely-used medication?

A: Yes, the active ingredient in Valvulan, Digoxin, is recognized globally as an important medicine. It is included in the World Health Organization's Model List of Essential Medicines, which signifies its established importance in clinical practice worldwide.


Q: What should I do if the side effects of Valvulan are bothersome?

A: Patient counseling information states that any bothersome side effect is important to discuss with a healthcare professional. Symptoms that are persistent or severe, such as nausea, vomiting, or visual changes, are noted as potential signs of toxicity and should lead to consultation with a healthcare professional.


Q: Are there any specific lifestyle changes recommended when taking Valvulan?

A: Official administration instructions emphasize the importance of maintaining consistent dosing times. Maintaining consistent potassium levels in the diet is important, as low potassium can increase toxicity risk. This should be managed under the guidance of a healthcare professional.


Q: Can Valvulan affect my energy levels during the day?

A: Due to its effects on the central nervous system, Valvulan can potentially cause dizziness, drowsiness, or fatigue in some patients. Unusual weakness or tiredness is specifically noted in safety information and should be monitored.


Q: Is Valvulan approved for use in children?

A: Yes, Valvulan is approved for use in the pediatric population, including infants, children, and adolescents, for certain regulated conditions. However, the dosing requires specialized, highly accurate calculations based on the child’s weight.


Q: What are the early signs that Valvulan is working?

A: The therapeutic goal of Valvulan is to improve the efficiency of your heart. Early signs that the medication is working as intended often include an improvement in symptoms of heart failure, such as reduced shortness of breath and a decrease in swelling (edema).


Q: Does taking Valvulan affect my ability to drive or operate machinery?

A: Valvulan can cause side effects like dizziness, visual disturbances (e.g., blurred vision), or other effects on the nervous system. Because of these effects, caution is generally recommended when driving or operating machinery until the individual is aware of how the medication affects them.


Q: Can herbal teas or natural remedies interact with Valvulan?

A: Yes, official drug interaction information notes that certain herbal products, such as St. John's Wort, can significantly affect how Valvulan works in the body. It is essential to ensure a healthcare professional is aware of all herbal teas or natural remedies being taken, as many of these may have documented or potential interactions with Valvulan.


Q: Is it normal to feel dizzy sometimes on Valvulan?

A: Dizziness is officially listed as a common side effect of Valvulan in regulatory documents. While it is a recognized effect, if the dizziness becomes severe or persistent, consultation with a healthcare provider is recommended.


Q: What if I experience stomach upset after taking Valvulan?

A: Mild stomach upset, nausea, or vomiting are noted as common side effects. However, if these symptoms become persistent, severe, or are accompanied by a loss of appetite, they are considered potential signs of drug toxicity, and professional medical evaluation is important in these cases.


Q: How is Valvulan stored and what is its shelf life?

A: Official storage instructions require that the product be kept at controlled room temperature, typically 20 C to 25 C. It must be kept in the original, tightly closed container away from moisture and light. The specific shelf life and expiration date are provided on the medication's packaging.


Q: Does Valvulan help to prevent future complications?

A: Clinical studies have shown that Valvulan is effective in reducing the rate of hospitalizations related to worsening heart failure. Preventing such hospitalizations is a major component of managing the chronic condition and avoiding acute complications.


Q: What kind of monitoring (blood tests, etc.) is needed while on Valvulan?

A: Because Valvulan has a narrow therapeutic index, close patient monitoring is mandatory. This typically involves periodic blood tests to check levels of key electrolytes, particularly potassium, and to assess kidney function.


Q: Can Valvulan cause changes in mood or behavior?

A: Yes, official adverse reaction reports include psychiatric and nervous system effects. Uncommon side effects like depression have been reported, and very rare effects such as psychotic disorders have also been noted, indicating potential changes in mood or behavior.


Q: What is the average time for Valvulan to reach its full effect?

A: According to the pharmacokinetics (how the drug moves through the body), Valvulan typically requires approximately seven days of consistent maintenance therapy to achieve stable, full therapeutic concentrations in the bloodstream, provided kidney function is normal.

How should Valvulan be stored and disposed of?

How to Store and Dispose of Valvulan

Official regulatory documents define strict requirements for storing and disposing of Valvulan to maintain its quality and ensure environmental safety.

Storage Requirements

Storage Factor Official Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the product in the original, tightly closed container to protect it from moisture and light.
Stability Any solution reconstituted or prepared must be used within the officially documented in-use period.

Disposal Instructions

Valvulan must not be disposed of in household trash or flushed down the toilet. Unused or expired medication must be taken to an authorized medicine take-back location or pharmaceutical waste collection program, adhering to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valvulan found in:

A-Z Index: